Posted by Michael Wonder on 16 Apr 2021
Mayne Pharma and Mithra announce FDA approval of new oral contraceptive Estelle
15 April 2021 - Mayne Pharma Group and Mithra Pharmaceuticals are very pleased to announce that the US FDA has approved the new drug application for the novel combined oral contraceptive Estelle under the trademark Nextstellis (15 mg Estetrol (E4) / 3 mg drospirenone).
Mayne Pharma anticipates the commercial launch of Estelle by the end of June 2021.
